Effects of Drugs that Modify Brain Monoamine Concentrations on Plasma Gonadotropin and Prolactin Levels in the Rat

Donoso, Alfredo O.; Bishop, Wendy Pechero; Fawcett, C. P.; Krulich, L.; McCann, Samuel M.

doi:10.1210/endo-89-3-774

Cited by 176 publications

(63 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, its effects have been assessed against two known stimuli to prolactin release in man: TRH, which has a direct pituitary action Lister et al, 1974); and 3-iodo-L-tyrosine (MIT), a potent inhibitor of tyrosine hydroxylase (Udenfriend et al, 1965), which selectively inhibits hypothalamic dopaminergic pathways and may also have DA receptor-blocking activity (Donoso et aL, 1971;Smythe et aL, 1974;Smythe et al, 1975). *Present address: Servicio de neuroendocrinologia, Facultad de Medicina, Ciudad Universitaria, Madrid.…”

Section: Introduction Methodsmentioning

confidence: 99%

Effects of nomifensine, an inhibitor of endogenous catecholamine re‐ uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man.

Scanlon¹,

Gómez-Pan²,

Mora³

et al. 1977

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Nomifensine, an inhibitor of endogenous catecholamine re-uptake, did not affect the growth hormone (GH) or prolactin levels in patients with acromegaly or hyperprolactinaemia. It does not, therefore, have any therapeutic role in these conditions at the dosage used in this study. 2 It had no effect on thyrotrophin-releasing hormone (TRH)-induced thyrotrophin (TSH) or prolactin release in males, yet caused marked suppression of monoiodotyrosine (MIT)-induced prolactin release in males but not in females. 3 The significant suppression of MIT-induced prolactin release in males is likely to reflect the dopamine (DA) agonist activity of the drug and its lack of effect in the other situations tested could be dose related.4 It is proposed that the difference in male and female patterns of prolactin response to MIT after nomifensine, could be due to a 'damping' effect of oestrogen on the hypothalamic dopaminergic system.

show abstract

Section: Introduction Methodsmentioning

confidence: 99%

Effects of nomifensine, an inhibitor of endogenous catecholamine re‐ uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man.

Scanlon¹,

Gómez-Pan²,

Mora³

et al. 1977

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…One of the consequences of increased hypothalamic DA activity following L-dopa administration is the significant reduction of prolactin secretion in both man (Kleinberg et al 1971) and experimental animals (Lu arid Meites 1971). Conversely, when DA action is blocked, there is a profound increase in prolactin secretion (Donoso et al 1971;Kleinberg et al 1971;Smythe and Lazarus 1973).…”

Section: Introductionmentioning

confidence: 99%

Acute Effects of Lithium on Central Dopamine and Serotonin Activity Reflected by Inhibition of Prolactin and Growth Hormone Secretion in the Rat

Smythe¹,

Brandstater²,

Lazarus³

1979

Aust. Jnl. Of Bio. Sci.

View full text Add to dashboard Cite

The acute administration of lithium chloride significantly inhibits both prolactin and growth hormone secretion in the rat. In terms of known neuroendocrine relationships this finding indicates that lithium administration alters both dopamine (DA) and serotonin (5-HT) activity in the hypothalamus. The data suggest that DA activity is increased (inhibiting prolactin release) and 5-HT activity is decreased (reducing growth hormone stimulation). The data are in agreement with fluorescent histological studies on the effects of chronic lithium administration and suggest that endocrine parameters may be used to provide neuropharmacological information about compounds which alter brain monoamine activity.

show abstract

“…The secretion of polypeptide hormones is readily affected by dopamine: inhibition of prolactin release is well documented in vivo (5,6) and in vitro (7); the growth hormone secretory system is responsive to dopaminergic agents (8,9); and both glucagon and insulin release are stimulated by dopamine (10), as are renin (11) and parathyroid hormone (12). With the exception of prolactin secretion (13,14), however, no physiologic role has hitherto been attributable to dopamine in the regulation of these endocrine systems, nor has it been established in man that the above hormonal responses are mediated through the interaction of dopamine with receptors different and independent from the well-described adrenergic receptors. A better pharmacologic characterization of the endocrine effects of dopamine is warranted in view of the multireceptor potential of the dopamine molecule (15).…”

Section: Introductionmentioning

confidence: 99%

Dopamine during α- or β-Adrenergic Blockade in Man

Lorenzi¹,

Karam²,

Tsalikian³

et al. 1979

J. Clin. Invest.

View full text Add to dashboard Cite

A B S T R A C T We studied the contribution of a-and ,3-adrenergic receptor activation to the cardiovascular, metabolic, and hormonal effects of dopamine. At a concentration of 1.5 ,ug/kg min, the infusion of dopamine in 12 normal volunteers was associated with a transient but significant rise in pulse rate, which was prevented by propranolol. Venous plasma glucose did not change throughout the experiments, and a mild increase in plasma free fatty acid levels observed during the administration of dopamine alone was antagonized by propranolol. In contrast, neither the /8-adrenergic blocker, propranolol, nor the a-adrenergic blocker, phentolamine, was effective in inhibiting the dopamine-induced rise in plasma glucagon (from 82+9 to 128±+14 pglml; P < 0.005) and serum insulin (from 7.5±+1 to 13±1.5 ,LU/ml; P < 0.005) or its suppression of plasma prolactin (from 8.5±1 to 5.2±0.8 ng/ml; P < 0.001). Although serum growth hormone levels did not change during the infusion of dopamine alone, an obvious rise occurred in three subjects during the combined infusion of propranolol and dopamine.Whereas some metabolic and cardiovascular effects of dopamine are mediated through adrenergic mechanisms, these observations indicate that this is not the case for the effects of this catecholamine on glucagon, insulin, and prolactin secretion, and thus provide further support for the theory of a specific dopaminergic sensitivity of these hormonal systems in man.

show abstract

Effects of Drugs that Modify Brain Monoamine Concentrations on Plasma Gonadotropin and Prolactin Levels in the Rat

Cited by 176 publications

References 0 publications

Effects of nomifensine, an inhibitor of endogenous catecholamine re‐ uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man.

Effects of nomifensine, an inhibitor of endogenous catecholamine re‐ uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man.

Acute Effects of Lithium on Central Dopamine and Serotonin Activity Reflected by Inhibition of Prolactin and Growth Hormone Secretion in the Rat

Dopamine during α- or β-Adrenergic Blockade in Man

Contact Info

Product

Resources

About